Page last updated: 2024-10-23

aztreonam and Candidiasis

aztreonam has been researched along with Candidiasis in 2 studies

Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.

Candidiasis: Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Dhanasekaran, S3
Selvadoss, PP3
Manoharan, SS3
Zingman, BS1

Other Studies

2 other studies available for aztreonam and Candidiasis

ArticleYear
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:3

    Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb

2023
Fever after cytotoxic therapy of chronic lymphocytic leukemia.
    Cancer investigation, 1999, Volume: 17, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aztreonam; Candidiasis; Female;

1999